Skip to main content
PMC home page
Springer logoLink to Springer
. 2022 Feb 16;42(3):512–513. doi: 10.1007/s10875-022-01219-3

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

Manuel Santamaria 1, Olaf Neth 2, Jo A Douglass 3,4, Gergely Krivan 5, Robin Kobbe 6, Ewa Bernatowska 7, Sofia Grigoriadou 8, Claire Bethune 9, Anita Chandra 10, Gerd Horneff 11,12, Michael Borte 13, Anja Sonnenschein 14, Pavlina Kralickova 15, Silvia Sánchez Ramón 16, Daman D Langguth 17, Luis Ignacio Gonzalez‑Granado 18, Laia Alsina 19,20,21,✉, Montse Querolt 22, Rhonda Griffin 23, Carrie Hames 23, Elsa Mondou 23, Jeffrey Price 23, Ana Sanz 22, Jiang Lin 23
PMCID: PMC9015977  PMID: 35174440

Correction to : Journal of Clinical Immunology

https://doi.org/10.1007/s10875-021-01181-6

Due to typesetting mistake, the author’s corrections were missed.

The original version has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Journal of Clinical Immunology are provided here courtesy of Springer

RESOURCES